

HEPATIC REVITALIZATION

CLINICAL APPLICATIONS

- *Helps to eliminate heavy metals from the body.*
- *Reduces bad cholesterol (LDL).*
- *Reduces calcium deposits in atherosclerotic plaques.*
- *Reduces the risk of cardiac arrhythmia.*
- *Improves intellectual function, memory and concentration.*

What is Lebercell?

Celltox is a potent cellular detoxification therapy designed to support the body's natural ability to eliminate harmful toxins and pollutants. This formula combines bioactive compounds and cellular extracts that aid in the removal of heavy metals, environmental toxins, and metabolic waste.

By enhancing cellular membrane flexibility and promoting systemic detoxification, Celltox helps rejuvenate tissues and optimize overall health.

Ideal for individuals exposed to environmental stressors, pollutants, or metabolic toxins, Celltox assists in cleansing and revitalizing the body at the cellular level.

Key Bioactive Compounds

Cellular extracts from liver and thymus gland; Lycopene; EDTA; R-Lipoic Acid; Vitamins D, C, and E.

Benefits

- Facilitates the removal of heavy metals and environmental toxins
- Promotes antioxidant protection against cellular damage
- Supports improved cognitive function and vitality
- Enhances immune system function and detoxification capacity

Highlights

- Targets heavy metal and toxin removal at the cellular level
- Includes antioxidants and bioactive extracts to support detoxification pathways
- Supports cellular regeneration and membrane flexibility
- Promotes overall system rejuvenation and immunity

Administration

Orally, consume before taking food to improve absorption, preferably with water in the morning.

Does Not Contain

Gluten, corn, yeast, artificial colors or flavors.

Composition:

Boxes of 30 tablets of 650 mg. / Boxes of 60 tablets of 650 mg. Each 650 mg gastro-resistant tablet contains:

Opothherapeutic Extracts: Liver, Kidney.

Peptide Extracts: Liver, Kidney.

Enzyme complexes: Superoxide Dismutase, Glutathion peroxidase, Glutathione Reductase, Glutathione Transferase, Adénosine triphosphate (ATP).

Other actives: Zinc, Selenium, Magnesium, Lycopène, EDTA (ethyl diamine tetra acetic acid), Zéolite-clinoptilolite micronisé, R-lipoic acid, Vitamine D, Vitamine C, Vitamine E, Cysteine, Glycine.

Other Ingredients: Stabilizers and Excipients..

- Opothherapeutic cell extracts: Liver

References

1. Oertel M. Hepatocyte transplantation: waiting for stem cells. J Gastroenterol. 2011 Aug;46(8):953-65.
<https://doi.org/10.1007/s00535-011-0427-5>
2. Hu XH, Xu X, et al. Cell therapy in end-stage liver disease: replace and remodel. Stem Cell Res Ther. 2023;14:141.
<https://doi.org/10.1186/s13287-023-03370-z>
3. Blockmans D, Persoons P, Van Houdenhove B, et al. Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome: a double-blind, crossover trial. Am J Med. 2006;119(2):167.e23-30.
<https://doi.org/10.1016/j.amjmed.2005.07.047>
4. Castellani A, et al. Hepatoprotective effect of a combination of UDPG, vitamin B12 and liver extract in psychiatric patients with liver diseases. Clin Ter. 1978;86(6):567-576.
<https://pubmed.ncbi.nlm.nih.gov/4609267>
5. WebMD. Liver Extract - Uses, Side Effects, and More.
<https://www.webmd.com/vitamins/ai/ingredientmono-1010/liver-extract>
6. ScienceDirect. Liver Extract - an overview.
<https://www.sciencedirect.com/topics/medicine-and-dentistry/liver-extract>

- Opothherapeutic cell extracts: Kidney

References

1. Huang J, Zhou L. Natural products for kidney disease treatment: Focus on targeting mitochondrial dysfunction. Front Pharmacol. 2023;14:114200. <https://doi.org/10.3389/fphar.2023.114200>
2. McGill MR, Jaeschke H. Cell-based therapies for experimental chronic kidney disease: a systematic review and meta-analysis. Clin Exp Pharmacol Physiol. 2015;42(12):1159–1169.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4348565/>
3. Gong X, et al. Therapeutic potential of natural products in the treatment of renal disorders. Pharmacol Res. 2022;176:106049.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182762/>

4. Tavazzi B, et al. A Pilot Study of a Natural Food Supplement as New Possible Therapeutic Strategy in Chronic Kidney Disease Patients. Pharmaceuticals (Basel). 2020;13(7):148.

<https://doi.org/10.3390/ph13070148>

- Opothherapeutic cell extracts: Thymus Gland

References

1. Fabris N, Mocchegiani E. Thymus, immunity, and aging: therapeutic effects of thymic hormones. Drugs Aging. 1992 Jan-Feb;2(1):20–29.
<https://doi.org/10.2165/00002512-199202010-00003>
2. Blesch A, Meyer M, Kuhn HG, et al. Thymic extracts improve T-cell function and regeneration in aged rats. Mech Ageing Dev. 1993 Oct;71(2):125–136.
[https://doi.org/10.1016/0047-6374\(93\)90029-6](https://doi.org/10.1016/0047-6374(93)90029-6)
3. Bach JF. The effects of thymus extracts on the immune response. Clin Exp Immunol. 1978 May;32(2):279–288.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1537490/>
4. Fabris N, Mocchegiani E, Provinciali M. Thymic hormone activity and aging: restoration of T-cell functions by thymopentin therapy in aged mice. Int J Immunopharmacol. 1983;5(2):121–128.
[https://doi.org/10.1016/0192-0561\(83\)90046-6](https://doi.org/10.1016/0192-0561(83)90046-6)

- Peptide Extracts: Liver

References

1. Demirtaş H, Özer A, Yıldırım AK, Dursun AD, Sezen ŞC, Arslan M. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia–Reperfusion Injury. Medicina. 2025;61(2):291.
<https://doi.org/10.3390/medicina61020291>
2. Ameliorative Effects of Peptide Phe-Leu-Ala-Pro on Acute Liver and Kidney Injury. ACS Omega. (2.5 years ago).
<https://doi.org/10.1021/acsomega.2c04851>
3. Effects of Compound Active Peptides on Protecting Liver and... PMC. (Publication date unspecified).
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157784/>
4. Ameliorating Effects of Bioactive Peptides Extracted from Litopenaeus vannamei Wastes on Oxidative Stress, Glucose Regulation, and Autophagy Gene Expression in Nonalcoholic Fatty Liver-Induced Rats. PMC. (2022).
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436606/>
5. Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy. 2022.
<https://doi.org/10.1038/s41392-022-00904-4>
6. Copper peptide GHK-Cu. Wikipedia. (last month).
https://en.wikipedia.org/wiki/Copper_peptide_GHK-Cu
7. Liver-expressed antimicrobial peptide (LEAP-2). Wikipedia. (7 months ago).
https://en.wikipedia.org/wiki/Liver-expressed_antimicrobial_peptide

- Peptide Extracts: Kidney

References

1. Urotensin-II as a peptide with systemic roles (including renal effects). Urotensin-II. Wikipedia.
<https://en.wikipedia.org/wiki/Urotensin-II>
2. Proenkephalin as a biomarker in acute kidney injury and



glomerular filtration. Wikipedia.

<https://en.wikipedia.org/wiki/Proenkephalin>

3. Renal metabolism of C-peptide in humans: renal uptake ~7× urinary excretion; metabolized by kidney. Zavaroni I, Deferrari G, Lugari R, et al. Renal metabolism of C-peptide in man. *J Clin Endocrinol Metab.* 1987;65(3):494–499. doi:10.1210/jcem-65-3-494. <https://pubmed.ncbi.nlm.nih.gov/3624411>

6. PEP-Z-2 peptide treats renal fibrosis in mice (UUO model). ScienceDirect. The novel peptide PEP-Z-2 potentially treats renal fibrosis in vivo. 2024.

<https://www.sciencedirect.com/science/article/abs/pii/S0014299924006319>

7. Urinary peptide markers distinguish CKD etiologies. MDPI. Recent Advances in Urinary Peptide and Proteomic Biomarkers in ... *Int J Mol Sci.* 2023;24(11):9156.

<https://www.mdpi.com/1422-0067/24/11/9156>

8. Universal urinary peptidomic signature predicts AKI early. BMC Critical Care. A universal predictive and mechanistic urinary peptide signature in ... 2022.

<https://ccforum.biomedcentral.com/articles/10.1186/s13054-022-04193-9>

10. Cyclic peptide agonist of BMP-7 receptor reverses kidney fibrosis. *Nature Reviews Nephrology.* An oral cyclic peptide drug to reverse kidney fibrosis? 2012.

<https://www.nature.com/articles/nrneph.2012.26>

- Peptide Extracts: Thymus Gland

References

1. Khavinson VK, Linkova NS, Dyatlova NM, Kuznik BI. Peptide preparation from thymus stimulates proliferation of thymocytes. *Bull Exp Biol Med.* 2002 Feb;133(2):166–168.

<https://doi.org/10.1023/A:1013996510219>

2. Khavinson VK, Morozov VG. Peptides of the thymus in the regulation of aging and carcinogenesis. *Neuro Endocrinol Lett.* 2003;24(5):329–335. <https://pubmed.ncbi.nlm.nih.gov/14647001/>

3. Morozov VG, Khavinson VK, Trofimova SV. The peptide thymogen and its effects on immune function. *Biomedicine.* 2001;1(1):29–35. <https://elibrary.ru/item.asp?id=7465887>

4. Gorbunov GV, Semenova LA, Kvetnoi IM. Immunocorrective effect of thymus peptides in stress and aging. *Adv Gerontol.* 2002;10:84–90. <https://elibrary.ru/item.asp?id=8914695>

5. Khavinson VK, Kuznik BI, Ryzhak GA, et al. Thymus peptide bioregulators restore T-cell immunity in elderly people. *Drugs Exp Clin Res.* 1997;23(2):73–79.

<https://pubmed.ncbi.nlm.nih.gov/9207234/>

- Other Actives: Lycopene

References

1. Rao AV, Agarwal S. Role of antioxidant lycopene in cancer and heart disease. *J Am Coll Nutr.* 2000 Oct;19(5):563–569.

<https://doi.org/10.1080/07315724.2000.10718953>

2. Stahl W, Sies H. Lycopene: a biologically important carotenoid for humans? *Arch Biochem Biophys.* 1996 Oct 1;336(1):1–9. <https://doi.org/10.1006/abbi.1996.0525>

3. Arab L, Steck S. Lycopene and cardiovascular disease. *Am J Clin Nutr.* 2000 Sep;71(6):1691S–1695S.

<https://doi.org/10.1093/ajcn/71.6.1691S>

4. Riso P, Visioli F, Grande S, Guarnieri S, Gardana C, Simonetti P, Porrini M. Effects of a tomato-based drink on markers of

inflammation, immunomodulation, and oxidative stress. *J Agric Food Chem.* 2006 Aug 9;54(16):2563–2566.

<https://doi.org/10.1021/jf060671p>

5. Sesso HD, Buring JE, Norkus EP, Gaziano JM. Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women. *Am J Clin Nutr.* 2005 Jan;79(1):47–53.

<https://doi.org/10.1093/ajcn/79.1.47>

- Other Actives: Zinc

References

1. Prasad AS. Zinc in human health: effect of zinc on immune cells. *Mol Med.* 2008;14(5-6):353–357.

<https://doi.org/10.2119/2008-00033.Prasad>

2. Roohani N, Hurrell R, Kelishadi R, Schulin R. Zinc and its importance for human health: An integrative review. *J Res Med Sci.* 2013;18(2):144–157.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724376/>

3. Hambidge KM. Zinc and health: current status and future directions. *J Nutr.* 2000;130(5S Suppl):1344S–1349S.

<https://doi.org/10.1093/jn/130.5.1344S>

4. Wessels I, Maywald M, Rink L. Zinc as a gatekeeper of immune function. *Nutrients.* 2017;9(12):1286.

<https://doi.org/10.3390/nu9121286>

5. Institute of Medicine. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington, DC: National Academies Press; 2001.

<https://www.ncbi.nlm.nih.gov/books/NBK222317/>

- Other Actives: Selenium

References

1. Rayman MP. The importance of selenium to human health. *Lancet.* 2000 Jul 15;356(9225):233–241.

[https://doi.org/10.1016/S0140-6736\(00\)02490-9](https://doi.org/10.1016/S0140-6736(00)02490-9)

2. Fairweather-Tait SJ, Bao Y, Broadley MR, et al. Selenium in human health and disease. *Antioxid Redox Signal.* 2011 Jun 15;14(7):1337–1383. <https://doi.org/10.1089/ars.2010.3275>

3. Hatfield DL, Tsuji PA, Carlson BA, Gladyshev VN. Selenium and selenocysteine: roles in cancer, health, and development. *Trends Biochem Sci.* 2014 Mar;39(3):112–120.

<https://doi.org/10.1016/j.tibs.2013.12.007>

4. Steinbrenner H, Speckmann B, Sies H. Toward understanding success and failures in the use of selenium for cancer prevention. *Antioxid Redox Signal.* 2013;19(2):181–191.

<https://doi.org/10.1089/ars.2012.4901>

5. Huang Z, Rose AH, Hoffmann PR. The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities. *Antioxid Redox Signal.* 2012 Apr 1;16(7):705–743. <https://doi.org/10.1089/ars.2011.4145>

- Other Actives: Glutathione Peroxidase

References

1. Brigelius-Flohé R, Maiorino M. Glutathione Peroxidase-1 in Health and Disease: From Molecular Mechanisms to Therapeutic Opportunities. *Antioxid Redox Signal.* 2011;15(7):1957–1997. Disponible en: <https://pmc.ncbi.nlm.nih.gov/articles/PMC3159114/>

2. Sedighi Zargari O, Varshi G, et al. Effect of Selenium



Supplementation on Glutathione Peroxidase Enzyme Activity in Patients With Chronic Kidney Disease: A Randomized Clinical Trial. *Nephro Urol Mon.* 2014 Mar;6(3):e17945. Disponible en: <https://pmc.ncbi.nlm.nih.gov/articles/PMC4090673/>

3. The role of glutathione peroxidase-1 in health and disease (revisión). *PubMed.* 2022. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/35691509/>

4. Sedighi O, Zargari M, Varshi G. Selenium supplementation on plasma glutathione peroxidase activity in patients with end-stage chronic renal failure. *Biol Trace Elem Res.* 2004 Jan;97(1):15–30. Disponible a través de SciSpace: <https://pdfs.semanticscholar.org/0be3/83c49d705221d0683f68ada8079eb65d3c9f.pdf>

5. Wikipedia. Glutathione peroxidase. Última modificación: hace 2 semanas. Disponible en: https://en.wikipedia.org/wiki/Glutathione_peroxidase

6. Tian R, Geng Y, Yang Y, Seim I, Yang G. Oxidative stress drives divergent evolution of the glutathione peroxidase (GPX) gene family in mammals. *Integr Zool.* 2021;16(5):696–711. DOI: <https://doi.org/10.1111/1749-4877.12521>

- Other Actives: Glutathione Reductase

References

1. Couto N, Wood J, Barber J. The role of glutathione reductase and related enzymes on cellular redox homeostasis. *Free Radical Biology & Medicine.* 2016 Jun;95:27–42. PMID: 26923386. <https://pubmed.ncbi.nlm.nih.gov/26923386/>

2. Narciso C, et al. Glutathione-Related Enzymes and Proteins: A Review. Published ~2.4 years ago. <https://pubmed.ncbi.nlm.nih.gov/PMC9919958/>

3. ScienceDirect Topics. Glutathione Reductase – overview. <https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/glutathione-reductase>

4. ScienceDirect Neuroscience. Glutathione Reductase is crucial in detoxifying peroxides. <https://www.sciencedirect.com/topics/neuroscience/glutathione-reductase>

5. Journal of Post-Coronary Research. Glutathione level and glutathione reductase activity in serum of coronary heart disease patients. <https://www.jpccr.eu/Glutathione-level-and-glutathione-reductase-activity-in-serum-of-coronary-heart-disease%2C81277%2C0%2C2.html>

6. PLOS ONE. Lüersen K, et al. The Glutathione Reductase GSR-1 Determines Stress Tolerance and Longevity in *Caenorhabditis elegans*. *PLoS ONE* 8(4): e60731. Apr 8, 2013. <https://doi.org/10.1371/journal.pone.0060731>

7. MDPI Medicina. Glutathione Reductase Is Associated with the Clinical Outcome of Septic Shock Patients Under Early-Initiated CVVH Treatment. <https://doi.org/10.3390/medicina57070689>

8. Wiley J Med Virol. Profiling serum levels of glutathione reductase and IL-10 in COVID-19 patients. <https://doi.org/10.1002/jmv.27464>

9. Archives of Medical Science. Establishing reference intervals for serum glutathione reductase in healthy adults. <https://www.archivesofmedicalscience.com/Establishing-reference-intervals-for-serum-glutathione-reductase-in-healthy-adults%2C199536%2C0%2C2.html>

10. Wikipedia. Glutathione reductase. https://en.wikipedia.org/wiki/Glutathione_reductase

- Other Actives: Glutathione Transferase

References

1. Salinas AE, Wong MG. Glutathione S-transferases—a review. *Curr Med Chem.* 1999 Apr;6(4):279–309. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/10101214/>

2. Sheehan D, Meade G, Foley VM, Dowd CA. Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily. *Biochem J.* 2001 Nov 15;360(Pt 1):1–16. Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1222196/>

3. Allocati N, Masulli M, Di Ilio C, Federici L. Glutathione transferases: substrates, inhibitors and pro-drugs in cancer and neurodegenerative diseases. *Oncogenesis.* 2018 Apr;7:8. Disponible en: <https://www.nature.com/articles/s41389-017-0025-3>

4. Vázquez-Martínez O et al. Glutathione S-transferase: A versatile and dynamic enzyme. *Biochem Biophys Res Commun.* 2024. Disponible en: <https://pubmed.ncbi.nlm.nih.gov/39366175/>

5. Mondal S, et al. The Multifaceted Role of Glutathione S-Transferases in Health and Disease. *Biomolecules.* 2022 Apr;13(4):688. Disponible en: <https://www.mdpi.com/2218-273X/13/4/688>

6. Wikipedia. Glutathione S-transferase. Actualizado hace 2 semanas. Disponible en: https://en.wikipedia.org/wiki/Glutathione_S-transferase

- Other Actives: Adenosine Triphosphate (ATP)

References

1. ATP Synthase – an overview | ScienceDirect Topics. <https://www.sciencedirect.com/topics/neuroscience/atp-synthase>

2. ATP synthase | enzyme – Britannica. <https://www.britannica.com/science/ATP-synthase>

3. Physiology, Adenosine Triphosphate – StatPearls (NCBI Bookshelf). <https://www.ncbi.nlm.nih.gov/books/NBK553175/>

4. ATP synthesis and storage – PMC – PubMed Central. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360099/>

5. F1-F₀ ATP Synthase/ATPase: Contemporary View on Unidirectional Catalysis – PubMed. <https://pubmed.ncbi.nlm.nih.gov/36982498/>

6. ATP synthase: Structure, Function and Inhibition – De Gruyter Brill. <https://www.degruyterbrill.com/document/doi/10.1515/bmc-2019-0001/html>

7. Structure of ATP synthase under strain during catalysis – Nature. <https://www.nature.com/articles/s41467-022-29893-2>

8. An overview of ATP synthase, inhibitors, and their toxicity – ScienceDirect. <https://www.sciencedirect.com/science/article/pii/S2405844023096676>

9. ATP Synthase and the Actions of Inhibitors Utilized To Study Its Roles – ASM Journals. <https://journals.asm.org/doi/10.1128/mmbr.00016-08>

11. Chemiosmosis – Wikipedia. <https://en.wikipedia.org/wiki/Chemiosmosis>

12. Adenosine triphosphate – Wikipedia. https://en.wikipedia.org/wiki/Adenosine_triphosphate

- Other Actives: Magnesium

References



1. Gröber, U., Schmidt, J., & Kisters, K. (2015). Magnesium in prevention and therapy. *Nutrients*, 7(9), 8199–8226.
<https://www.mdpi.com/2072-6643/7/9/5388>
2. Rosanoff, A., Weaver, C. M., & Rude, R. K. (2012). Suboptimal magnesium status in the United States: Are the health consequences underestimated? *Nutrition Reviews*, 70(3), 153–164.
<https://academic.oup.com/nutritionreviews/article/70/3/153/1933041>
3. DiNicolantonio, J. J., O'Keefe, J. H., & Wilson, W. (2018). Subclinical magnesium deficiency: A principal driver of cardiovascular disease and a public health crisis. *Open Heart*, 5(1), e000668. <https://openheart.bmj.com/content/5/1/e000668>
4. de Baaij, J. H. F., Hoenderop, J. G. J., & Bindels, R. J. M. (2015). Magnesium in man: Implications for health and disease. *Physiological Reviews*, 95(1), 1–46.
<https://journals.physiology.org/doi/full/10.1152/physrev.00012.2014>
5. Volpe, S. L. (2013). Magnesium in disease prevention and overall health. *Advances in Nutrition*, 4(3), 378S–383S.
<https://academic.oup.com/advances/article/4/3/378S/4558104>

- Other Actives: EDTA (Ethyldiaminetetraacetic Acid)

References

1. Crinnion, W. J. (2011). EDTA chelation therapy for vascular disease: A review of the literature. *Alternative Medicine Review*, 16(1), 22–29.
<https://www.altmedrev.com/archive/publications/16/1/22.pdf>
2. Lamas, G. A., Goertz, C., Boineau, R., et al. (2013). Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: The TACT randomized trial. *JAMA*, 309(12), 1241–1250.
<https://jamanetwork.com/journals/jama/fullarticle/1672238>
3. Waters, R. S., Bryden, N. A., Evans, G. W. (2001). EDTA chelation in toxic metal removal: clinical studies and safety. *Journal of Advancement in Medicine*, 14(1), 5–14.
<https://journals.sagepub.com/doi/pdf/10.1177/153537020113601209>
4. Guldager, B., Jørgensen, S. J., Jørgensen, P. J., & Høst, A. (1992). Chelation therapy with EDTA in patients with intermittent claudication: A double-blind, placebo-controlled study. *Circulation*, 86(2), 444–450.
<https://www.ahajournals.org/doi/10.1161/01.CIR.86.2.444>
5. Flora, S. J. S., & Pachauri, V. (2010). Chelation in metal intoxication. *International Journal of Environmental Research and Public Health*, 7(7), 2745–2788.
<https://www.mdpi.com/1660-4601/7/7/2745>

- Other Actives: Micronized Zeolite Clinoptilolite

References

1. Pavelić, K., Hadžija, M., Bedrica, L., et al. (2001). Natural zeolite clinoptilolite: new adjuvant in anticancer therapy. *Journal of Molecular Medicine*, 78(12), 708–720.
<https://link.springer.com/article/10.1007/s001090000166>
2. Lamprecht, M., Bogner, S., Steinbauer, K., et al. (2015). Effects of zeolite supplementation on parameters of intestinal barrier integrity, inflammation, redoxbiology and performance in aerobically trained subjects. *Journal of the International Society of Sports Nutrition*, 12, 40.
<https://jissn.biomedcentral.com/articles/10.1186/s12970-015-0092-5>
3. Kraljević Pavelić, S., Simović Medica, J., Gumbarević, D., et al.

- (2018). Critical review on zeolite clinoptilolite safety and medical applications in vivo. *Frontiers in Pharmacology*, 9, 1350.
<https://www.frontiersin.org/articles/10.3389/fphar.2018.01350/full>
4. Ivkovic, S., Deutsch, U., & Mijatovic, S. (2004). Dietary supplementation with clinoptilolite in patients with colorectal cancer: A randomized, double-blind, placebo-controlled study. *Anticancer Research*, 24(5B), 3121–3126.
<https://ar.iijournals.org/content/24/5B/3121.long>

- Other Actives: R-Lipoic Acid

References

1. Packer, L., Witt, E. H., & Tritschler, H. J. (1995). Alpha-lipoic acid as a biological antioxidant. *Free Radical Biology and Medicine*, 19(2), 227–250.
<https://www.sciencedirect.com/science/article/abs/pii/0891584995001747>
2. Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R., & Hagen, T. M. (2009). Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1790(10), 1149–1160.
<https://www.sciencedirect.com/science/article/pii/S0304416509001842>
3. Ghibu, S., Richard, C., Vergely, C., & Rochette, L. (2009). Antioxidant properties of alpha-lipoic acid and its potential therapeutic effects in diabetes. *Archives of Physiology and Biochemistry*, 115(1), 28–36.
<https://www.tandfonline.com/doi/abs/10.1080/13813450902757483>
4. Zhang, W. J., & Frei, B. (2007). Alpha-lipoic acid inhibits TNF- α -induced NF- κ B activation and adhesion molecule expression in human aortic endothelial cells. *The FASEB Journal*, 21(11), 1971–1983.
<https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.06-7831.com>

- Other Actives: Vitamin D

References

1. Holick, M. F. (2007). Vitamin D deficiency. *New England Journal of Medicine*, 357(3), 266–281.
<https://www.nejm.org/doi/full/10.1056/NEJMr070553>
2. Holick, M. F., & Chen, T. C. (2008). Vitamin D deficiency: a worldwide problem with health consequences. *The American Journal of Clinical Nutrition*, 87(4), 1080S–1086S.
<https://academic.oup.com/ajcn/article/87/4/1080S/4650426>
3. Ross, A. C., Taylor, C. L., Yaktine, A. L., & Del Valle, H. B. (Eds.). (2011). *Dietary Reference Intakes for Calcium and Vitamin D*. National Academies Press.
<https://www.ncbi.nlm.nih.gov/books/NBK56070/>
4. Wacker, M., & Holick, M. F. (2013). Sunlight and Vitamin D: A global perspective for health. *Dermato-Endocrinology*, 5(1), 51–108.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3897598/>
5. Pludowski, P., Holick, M. F., Grant, W. B., et al. (2013). Vitamin D supplementation guidelines. *Journal of Steroid Biochemistry and Molecular Biology*, 136, 38–54.
<https://www.sciencedirect.com/science/article/abs/pii/S096007601200165X>

- Other Actives: Vitamin C

References

1. Carr, A. C., & Maggini, S. (2017). Vitamin C and Immune Function. *Nutrients*, 9(11), 1211.



<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707683/>

2. Hemilä, H., & Chalker, E. (2013). Vitamin C for preventing and treating the common cold. *Cochrane Database of Systematic Reviews*, Issue 1.

<https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000980.pub4/full>

3. Padayatty, S. J., et al. (2003). Vitamin C as an antioxidant: evaluation of its role in disease prevention. *Journal of the American College of Nutrition*, 22(1), 18–35.

<https://www.tandfonline.com/doi/abs/10.1080/07315724.2003.10719272>

4. Frei, B., & Traber, M. G. (2001). The new US dietary reference intakes for vitamins C and E. *Redox Report*, 6(1), 5–9.

<https://pubmed.ncbi.nlm.nih.gov/11464038/>

5. Levine, M., Rumsey, S. C., Daruwala, R., Park, J. B., & Wang, Y. (1999). Criteria and recommendations for vitamin C intake. *JAMA*, 281(15), 1415–1423.

<https://jamanetwork.com/journals/jama/fullarticle/188749>

- Other Actives: Vitamin E

References

1. Traber, M. G., & Atkinson, J. (2007). Vitamin E, antioxidant and nothing more. *Free Radical Biology and Medicine*, 43(1), 4–15.

<https://doi.org/10.1016/j.freeradbiomed.2007.03.024>

2. Jiang, Q. (2014). Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. *Free Radical Biology and Medicine*, 72, 76–90.

<https://doi.org/10.1016/j.freeradbiomed.2014.03.035>

3. Sen, C. K., Khanna, S., & Roy, S. (2006). Tocotrienols: Vitamin E beyond tocopherols. *Life Sciences*, 78(18), 2088–2098.

<https://doi.org/10.1016/j.lfs.2005.12.001>

4. Brigelius-Flohé, R., & Traber, M. G. (1999). Vitamin E: function and metabolism. *FASEB Journal*, 13(10), 1145–1155.

<https://doi.org/10.1096/fasebj.13.10.1145>

5. Meydani, S. N., et al. (1997). Vitamin E supplementation and in vivo immune response in healthy elderly subjects. *JAMA*, 277(17), 1380–1386.

<https://jamanetwork.com/journals/jama/fullarticle/415252>

- Other Actives: Cysteine

References

1. Atkuri, K. R., Mantovani, J. J., Herzenberg, L. A., & Herzenberg, L. A. (2007). N-Acetylcysteine—a safe antidote for cysteine/glutathione deficiency. *Current Opinion in Pharmacology*, 7(4), 355–359. <https://doi.org/10.1016/j.coph.2007.04.005>

2. Zafarullah, M., Li, W. Q., Sylvester, J., & Ahmad, M. (2003). Molecular mechanisms of N-acetylcysteine actions. *Cellular and Molecular Life Sciences*, 60(1), 6–20.

<https://doi.org/10.1007/s000180300001>

3. Rushworth, G. F., & Megson, I. L. (2014). Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. *Pharmacology & Therapeutics*, 141(2), 150–159.

<https://doi.org/10.1016/j.pharmthera.2013.09.006>

4. Kelly, G. S. (1998). Clinical applications of N-acetylcysteine. *Alternative Medicine Review*, 3(2), 114–127.

<https://www.altmedrev.com/archive/publications/3/2/114.pdf>

5. Samuni, Y., Goldstein, S., Dean, O. M., & Berk, M. (2013). The

chemistry and biological activities of N-acetylcysteine. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1830(8), 4117–4129. <https://doi.org/10.1016/j.bbagen.2013.04.016>

- Other Actives: Glycine

References

1. Wu, G., & Gilbreath, K. R. (2018). Glycine and its potential protective role in oxidative stress and inflammatory diseases. *Amino Acids*, 50, 173–180.

<https://doi.org/10.1007/s00726-017-2511-5>

2. Razak, M. A., Begum, P. S., Viswanath, B., & Rajagopal, S. (2017). Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. *Oxidative Medicine and Cellular Longevity*, 2017, 1716701. <https://doi.org/10.1155/2017/1716701>

3. Kawai, N., Saika, R., Watanabe, M., & Satoh, M. (2012). Glycine as a neurotransmitter. In: Squire LR (ed) *Encyclopedia of Neuroscience*.

<https://doi.org/10.1016/B978-008045046-9.00110-3>

4. Albrecht, J., & Schousboe, A. (2005). Taurine interaction with neurotransmitter receptors in the CNS: An update. *Neurochemical Research*, 30(12), 1615–1621.

<https://doi.org/10.1007/s11064-005-8827-4>

5. Wang, W., Wu, Z., Dai, Z., Yang, Y., Wang, J., & Wu, G. (2013). Glycine metabolism in animals and humans: implications for nutrition and health. *Amino Acids*, 45(3), 463–477.

<https://doi.org/10.1007/s00726-013-1493-1>



Result Observational Studies

Lebercell® - Hepatic Revitalization Function

Results of observational studies for the indication of the treatment of the following medical parameters.

Preventive therapeutic action in patients with some genetic predisposition.

The therapeutic action as a primary treatment in patients with degenerative diseases that for several years were treated with conventional medicine and the expected results are not observed.

The therapeutic action as an adjuvant or reinforcement in the chaos of various pathologies combined with

Medical Expertise

Medical professionals feel safe and supported when using a LEBERCELL® treatment.

Intoxications

Patients working with heavy metals experienced improvement of heavy metal poisoning symptoms.

Vitality

The use of Celltox increases vitality and improves the physical condition of patients.

Interaction with other treatments

Doctors report that Celltox treatment has no negative effects on conventional treatments.

Adjuvant

Doctors report that the effect is more rapid in the majority of patients.

Joint diseases

Improvements in symptoms of osteoarthritis and rheumatoid arthritis are reported in patients undergoing other treatments.

